Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov;104(11):2200-2205.
doi: 10.3324/haematol.2018.213108. Epub 2019 Apr 4.

Distinguishing essential thrombocythemia JAK2 V617F from polycythemia vera: limitations of erythrocyte values

Affiliations

Distinguishing essential thrombocythemia JAK2 V617F from polycythemia vera: limitations of erythrocyte values

Richard T Silver et al. Haematologica. 2019 Nov.

Abstract

Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera is difficult because of shared mutation and phenotypic characteristics. The World Health Organization suggested hemoglobin and hematocrit values to diagnose polycythemia vera (PV), but their sensitivity and specificity were not tested. Moreover, red cell values do not accurately predict red cell mass, which we use to discriminate essential thrombocythemia JAK2V617F from PV. Eighty-three PV and 39 essential thrombocythemia JAK2V617F patients were diagnosed based on JAK2V617F positivity, chromium-51 red cell mass, and marrow biopsy findings. Red cell values used to construct a receiver operating characteristic analysis determined optimal thresholds for distinguishing essential thrombocythemia JAK2V617F from PV. Red cell value frequencies were plotted determining if overlap existed. Chromium-51 red cell mass separated PV from essential thrombocythemia JAK2V617F, but red cell values overlapped in 25.0-54.7%. Our data indicate that a significant proportion of PV patients may be underdiagnosed by using only red cell values. A bone marrow biopsy was performed in 199 of 410 (48.5%) and a serum erythropoietin value was measured in 225 of 410 (54.9%) of potential PV patients at our institution. Without isotope studies, marrow biopsies and serum erythropoietin values should improve diagnostic accuracy and become mandatory, but clinical data suggest these tests have not been routinely performed. Therefore, the clinical hematologist must be aware of imperfect accuracy when using only red cell values for distinguishing essential thrombocythemia JAK2V617F from PV.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Receiver operating characteristic (ROC) analysis curves of red cell values in men with polycythemia vera (PV) versus men with essential thrombocythemia (ETJAK2V617F) (triangle markers) and women with PV versus women with ETJAK2V617F (diamond markers). (A) For hematocrit (HCT), (B) for hemoglobin (HGB), and (C) for red blood cells (RBC).
Figure 2.
Figure 2.
Frequencies of red cell values in men and women with polycythemia vera (PV) (dotted curve) and essential thrombocythemia (ETJAK2V617F) (dashed curve). Proposed thresholds shown in black, vertical line. (A) For hematocrit (HCT), (B) for hemoglobin (HGB), and (C) for red blood cells (RBC).

Comment in

Similar articles

Cited by

References

    1. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092–1097. - PubMed
    1. Barbui T, Thiele J, Kvasnicka HM, Carobbio A, Vannucchi AM, Tefferi A. Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification. Leukemia. 2014: 28(10):2092–2094. - PubMed
    1. Spivak JL. Myeloproliferative Neoplasms. N Engl J Med. 2017;377(9):895–896. - PubMed
    1. Silver RT, Chow W, Orazi A, Arles SP, Goldsmith SJ. Evaluation of WHO Criteria for Diagnosis of Polycythemia Vera: A Prospective Analysis. Blood. 2013; 22(11):1881–1886. - PubMed
    1. Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Exp Rev Hematol. 2013;6(1):49–58. - PubMed

Publication types